InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.645 0.015 (0.92%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$1,620 Update - Consolidation/Split - PYC 13 Nov 2024 3:06PM $0.190 $1.645 risen by 765.79%
$1,620 Results of Annual General Meeting 13 Nov 2024 3:01PM $0.190 $1.645 risen by 765.79%
$1,620 2024 AGM Chairman's Address and CEO Presentation 13 Nov 2024 9:31AM $0.195 $1.645 risen by 743.59%
$1,620 Consolidation/Split - PYC 11 Nov 2024 6:04PM $0.195 $1.645 risen by 743.59%
$1,620 Annual General Meeting - Conference Call Details 6 Nov 2024 5:51PM $0.190 $1.645 risen by 765.79%
$1,620 RP11 SRC Approves Dose Escalation to Final Patient Cohort 5 Nov 2024 9:25AM $0.190 $1.645 risen by 765.79%
$1,620 First ADOA Patient Dosed in Clinical Trial 1 Nov 2024 9:16AM $0.185 $1.645 risen by 789.19%
$1,620 Presentation of RP11 Single Dose Data at RANZCO 31 Oct 2024 9:42AM $0.175 $1.645 risen by 840%
$1,620 Quarterly Activities/Appendix 4C Cash Flow Report 25 Oct 2024 5:11PM $0.180 $1.645 risen by 813.89%
$1,620 Interim Update on Progress in RP11 Repeat Dose Trials 22 Oct 2024 9:37AM $0.200 $1.645 risen by 722.50%
$1,620 Trading Halt 21 Oct 2024 9:08AM $0.200 $1.645 risen by 722.50%
$1,620 US FDA Grants Orphan Drug Designation to PYC Drug Candidate 21 Oct 2024 8:35AM $0.200 $1.645 risen by 722.50%
$1,620 Notice of Annual General Meeting/Proxy Form 14 Oct 2024 4:24PM $0.200 $1.645 risen by 722.50%
$1,620 2024 Corporate Governance Statement & Appendix 4G 9 Oct 2024 6:00PM $0.175 $1.645 risen by 840%
$1,620 Annual Report to shareholders 9 Oct 2024 5:56PM $0.175 $1.645 risen by 840%
$1,620 E&P Healthcare Conference Presentation 26 Sep 2024 8:53AM $0.155 $1.645 risen by 961.29%
$1,620 FDA Grants Rare Pediatric Disease Designation to PYC-001 30 Aug 2024 8:26AM $0.130 $1.645 risen by 1,165.38%
$1,620 Q3 2024 Investor Webinar Presentation 30 Aug 2024 8:08AM $0.130 $1.645 risen by 1,165.38%
$1,620 Appendix 4E and Audited Financial Statements 29 Aug 2024 5:15PM $0.130 $1.645 risen by 1,165.38%
$1,620 Q3 Investor Webinar 30 August 2024 22 Aug 2024 10:49AM $0.120 $1.645 risen by 1,270.83%
$1,620 PYC to Start Human Trials in Second Blinding Eye Disease 15 Aug 2024 8:57AM $0.105 $1.645 risen by 1,466.67%
$1,620 Canaccord Genuity Growth Conference Presentation 13 Aug 2024 9:03AM $0.105 $1.645 risen by 1,466.67%
$1,620 Visual Improvement in Multiple RP11 Patients 12 Aug 2024 8:50AM $0.110 $1.645 risen by 1,395.45%
$1,620 RP11 Clinical Trial Update - Amended 5 Aug 2024 10:31AM $0.105 $1.645 risen by 1,466.67%
$1,620 RP11 Clinical Trial Update 5 Aug 2024 8:56AM $0.097 $1.645 risen by 1,595.88%

176 - 200 of 961 results

Page 8 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.